The global myeloproliferative disorder drugs market size is expected to be valued at USD 9.26 billion by 2023., expanding at a CAGR of 3.4% during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market.Therapeutic development in second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.
Chronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group.The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.
Further key findings from the report suggest:
This product will be delivered within 1-3 business days.
Chronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group.The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.
Further key findings from the report suggest:
- The U.S. accounted for more than 45.0% of the market in 2017. Spiraling adoption of novel therapeutics and multiple product launches during the forecast period are anticipated to support the prominence of the market in global arena over the coming years
- Strong unmet needs are likely to shape the future of the market and encourage development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
- Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte and Teva. Primary go-to strategies of prominent players include collaborations for development and regional expansion in emerging markets.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Myeloproliferative Disorders Drugs Market Overview
Chapter 5 Myeloproliferative Disorders Market: Pipeline Intelligence
Chapter 6 Company Profiles
Chapter 7 Market Outlook
List of Tables
List of Figures
Companies Mentioned
- Novartis
- Bristol-Myers Squibb
- Pfizer
- Takeda
- Inctye
- Teva
Methodology
LOADING...
